Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Eye disorders – page 16

  • 373 clinical trials
  • 123 recruiting
  • 138 conditions
  • 27 countries

Conditions in this area

138 conditions with trials, the busiest first

Conjunctivitis allergic34Sjogren's syndrome31Endocrine ophthalmopathy26Neovascular age-related macular degeneration23Giant cell arteritis18Seasonal allergy17Uveal melanoma17Dry age-related macular degeneration16Rhinitis allergic16Diabetic retinal oedema13Dry eye12Age-related macular degeneration11Retinitis pigmentosa11Asthma10Graves' disease10Myopia10Glaucoma8Open angle glaucoma8Uveitis8Immunoglobulin G4 related disease7Behcet's syndrome6Cataract6Mite allergy6Neuromyelitis optica spectrum disorder6+114

Clinical trials in Eye disorders

373 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

373 clinical trials

Ulcerative keratitis

Not yet recruiting

Study on the Effectiveness of NANOULCOR for Patients with Severe Corneal Ulcers Using Allogenic Limbal Cells and Keratocytes

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Allogenic Corneal-Derived Adult Keratocytes, Ex-Vivo Expanded
  • Sponsor:Fundacion Publica Para La Investigacion Biosanitaria De Andalucia Oriental Alejandro Otero

Glaucoma

Not yet recruiting

Study Comparing Lidocaine Gel and Tetracaine/Oxybuprocaine Eye Drops for Anesthesia in Glaucoma Patients Undergoing Needling Procedures

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Anhydrous Lidocaine Hydrochloride
  • Sponsor:Hospital Del Mar

Macular oedema

Not yet recruiting

Study on the Effects of RO7200220 for Patients with Uveitic Macular Edema

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Humanised IgG2 monoclonal antibody against INTERLEUKIN-6
  • Sponsor:F. Hoffmann-La Roche AG

Immunoglobulin G4 related disease+3

Not yet recruiting

Study on the Safety and Effectiveness of Filgotinib for Patients with Refractory Behcet's Disease, Idiopathic Inflammatory Myopathies, and IgG4-Related Disease

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Filgotinib
  • Sponsor:Universitair Medisch Centrum Utrecht

Sjogren's syndrome

Not recruiting

Efficacy and Safety Evaluation of Dazodalibep in Patients with Moderate-to-Severe Systemic Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Sjogren's syndrome

Not recruiting

Evaluation of Dazodalibep Efficacy and Safety in Patients with Moderate-to-Severe Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Sjogren's syndrome

Not recruiting

A Study Testing Imeroprubart for Adults with Primary Sjogren's Disease with Moderate to Severe Symptoms

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Imeroprubart
  • Sponsor:Immunovant Sciences GmbH

Sjogren's syndrome

Not recruiting

Study on the Effectiveness and Safety of Nipocalimab for Adults with Moderate to Severe Sjögren's Disease

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Nipocalimab
  • Sponsor:Janssen Cilag International

Sjogren's syndrome

Not recruiting

Study on the Effectiveness and Safety of Efgartigimod for Adults with Primary Sjögren's Syndrome

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Sjogren's syndrome

Not recruiting

Safety Study of Efgartigimod in Adults with Primary Sjögren's Syndrome

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Conjunctivitis allergic+1

Not recruiting

Study on the Effectiveness of PURETHAL Mites for Adults with Moderate to Severe Allergic Rhinitis or Rhinoconjunctivitis Due to House Dust Mite Allergy

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Aluminium Hydroxide
  • Sponsor:HAL Allergy B.V.

Sjogren's syndrome

Not recruiting

Study on the Effects of HZN-1116 for Patients with Sjögren’s Syndrome

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:VIB1116
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Substances studied in this area

The therapies tested most often in Eye disorders trials.

Aflibercept27 clinical trialsSodium Chloride16 clinical trialsPrednisone14 clinical trialsRanibizumab14 clinical trialsDexamethasone11 clinical trialsDexamethasone Phosphate10 clinical trialsFluorescein Sodium10 clinical trialsPrednisolone10 clinical trialsNivolumab8 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.